Compare GKOS & PNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GKOS | PNR |
|---|---|---|
| Founded | 1998 | 1966 |
| Country | United States | United Kingdom |
| Employees | 1094 | N/A |
| Industry | Medical/Dental Instruments | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.9B | 10.1B |
| IPO Year | 2015 | 2003 |
| Metric | GKOS | PNR |
|---|---|---|
| Price | $185.49 | $66.07 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 16 |
| Target Price | ★ $126.92 | $109.73 |
| AVG Volume (30 Days) | 855.1K | ★ 3.2M |
| Earning Date | 04-29-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 1.34% |
| EPS Growth | N/A | ★ 5.88 |
| EPS | N/A | ★ 1.05 |
| Revenue | ★ $507,442,000.00 | N/A |
| Revenue This Year | $23.32 | $4.24 |
| Revenue Next Year | $27.43 | $4.82 |
| P/E Ratio | ★ N/A | $63.68 |
| Revenue Growth | ★ 32.33 | N/A |
| 52 Week Low | $73.16 | $57.60 |
| 52 Week High | $189.69 | $113.95 |
| Indicator | GKOS | PNR |
|---|---|---|
| Relative Strength Index (RSI) | 74.68 | 44.23 |
| Support Level | $99.75 | $57.60 |
| Resistance Level | N/A | $77.03 |
| Average True Range (ATR) | 7.77 | 1.91 |
| MACD | 1.39 | 0.29 |
| Stochastic Oscillator | 88.29 | 30.91 |
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
Pentair is a global leader in the water treatment industry, with 10,000 employees and a presence in 25 countries. Its business is organized into three segments: pool, water technologies, and flow. The company offers a wide range of water solutions, including energy-efficient swimming pool equipment, filtration solutions, and commercial and industrial pumps. Pentair generated approximately $4.2 billion in revenue in 2025.